'Blockbuster' Stem Cell Therapy?
Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data
Impressive, though early stage, Phase I data already has Pluristem Therapeutics Inc. setting the stage for Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. (BioWorld Today)